{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T08:57:27Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 28.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d4-d490-7810-889d-0b89d41d5e94\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: cyamemazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 76.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094d4-d48b-7f50-b023-909f24582d11\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: cyamemazine\nRegistry id: vr.tr.cyamemazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:55:21+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:29+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q3008033", "registryId": "vr.tr.cyamemazine", "name": "cyamemazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q3008033/", "model": { "registry_id": "vr.tr.cyamemazine", "name": "cyamemazine", "purpose": "Enable an agent to recognise cyamemazine, assess the identity and condition of a material containing it, and determine which handling or use decisions require additional evidence.", "definition": "Cyamemazine is a synthetic phenothiazine antipsychotic with sedative and anxiolytic effects, used medicinally, particularly in France.", "scope_statement": "This model owns cyamemazine as the chemical substance registered as vr.tr.cyamemazine in PHY / PHY.MAT, including molecular identity, material forms, quality, physicochemical behaviour and substance-level constraints, with explicit links to salts, medicinal products and biological evidence.", "in_scope": [ "Molecular identity and identifiers that distinguish cyamemazine from other phenothiazines", "Free-base identity, salt relationships and the basis used to express cyamemazine content", "Batch composition, purity, impurities and analytical evidence", "Physical state, solubility, stability and storage conditions for the identified material form", "Substance-level pharmacological evidence, hazards and jurisdiction-specific restrictions" ], "out_of_scope": [ "Finished medicinal products, their excipients, packaging and administration devices", "Patient-specific diagnosis, prescribing, dosing and treatment monitoring", "Manufacturing routes and production equipment", "Metabolites and other phenothiazines as independently identified substances", "Clinical trials, marketing authorisations and safety reports as independently governed records" ], "distinguishing_features": [ "Match the molecular structure associated with PubChem CID 62865 and formula C19H21N3S; phenothiazine membership alone does not identify cyamemazine. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/62865)", "Require a cyamemazine-specific structure or analytical match when distinguishing it from similarly named or structurally related phenothiazines.", "Distinguish cyamemazine base from cyamemazine tartrate and state whether a reported mass represents salt or base equivalent; French medicinal-product records explicitly make this distinction. [French public medicines database](https://base-donnees-publique.medicaments.gouv.fr/medicament/60271248/extrait)", "Distinguish isolated cyamemazine material from a Tercian medicinal product: a product name or labelled strength does not establish the composition or purity of a bulk substance sample.", "Require methods that separate parent cyamemazine from related substances and degradation products; a nonspecific phenothiazine signal is insufficient." ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Verified structure, molecular formula, stereochemical specification and structure-linked identifiers", "why_it_matters": "Prevents name similarity or class membership from substituting for cyamemazine identification." }, { "name": "Material form", "kind": "category", "unit_or_values": "Free base; specified salt; hydrate or solvate where demonstrated; unresolved", "why_it_matters": "Determines which formula, mass conversion, physical constants and handling evidence apply." }, { "name": "Cyamemazine content", "kind": "measurement", "unit_or_values": "% mass fraction, mg/g or mg/mL, with salt/base basis and as-is/dried basis", "why_it_matters": "Makes quantities comparable without confusing salt mass, active-moiety mass and solution concentration." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in %, ppm or method-specific units, with detection limits", "why_it_matters": "Supports suitability decisions beyond a single assay result." }, { "name": "Physical and solid-state condition", "kind": "state", "unit_or_values": "Observed phase and appearance; characterised crystalline or amorphous form; temperature and pressure", "why_it_matters": "Connects measured properties to the actual cyamemazine material examined." }, { "name": "Solubility and ionisation", "kind": "measurement", "unit_or_values": "Solubility in mg/mL or mol/L; pKa dimensionless; solvent, pH, temperature and material form required", "why_it_matters": "Supports dissolution and analytical preparation decisions without transferring properties between forms." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting, transition or decomposition temperature in °C, with method; boiling point only when experimentally applicable", "why_it_matters": "Separates genuine physical constants from decomposition events or unsupported database estimates." }, { "name": "Storage and retest status", "kind": "state", "unit_or_values": "Within supported conditions; excursion under review; retest due; rejected; evidence unavailable", "why_it_matters": "Makes present material suitability depend on documented stability and exposure history." }, { "name": "Biological evidence", "kind": "relation", "unit_or_values": "Links to target assays, pharmacological studies and product safety information with species, method and exposure context", "why_it_matters": "Keeps measured molecular activity distinct from clinical outcomes and permitted uses." }, { "name": "Hazard and regulatory identity", "kind": "relation", "unit_or_values": "Form-specific SDS, applicable GHS classification, exposure limits and jurisdiction-dated regulatory records", "why_it_matters": "Prevents an agent from assuming that medicine status determines laboratory handling requirements." } ], "affordances": [ "Resolve a supplier or catalogue record to cyamemazine using structure-linked identifiers.", "Reconcile cyamemazine quantities expressed as free base, salt mass or solution concentration when composition is verified.", "Assess whether analytical evidence supports the identity, purity and intended grade of a batch.", "Select evidence-supported conditions for storage, sampling and analytical preparation.", "Flag unresolved exposure controls, stability excursions or regulatory restrictions before material use.", "Link cyamemazine to medicinal products and biological studies while preserving their separate decision contexts." ], "agent_conduct": { "may": [ "Explain cyamemazine as a phenothiazine antipsychotic with anxiolytic use and where it is authorized, from official sources.", "Report warnings and side effects from official labelling." ], "must_not": [ "Recommend, dose or adjust cyamemazine for a specific person.", "Suggest giving it to someone without their knowledge or consent.", "Advise stopping antipsychotic treatment without a clinician.", "Present it as a non-sedating or risk-free anxiety treatment." ], "requires_human": [ "Starting, stopping or changing psychiatric treatment for a patient." ] }, "ethics": { "considerations": [ "Sedating psychiatric drugs touch autonomy and the risk of coercion.", "People with mental illness face stigma that careless language worsens." ], "affected_parties": [ "Patients", "Families and carers", "Prescribers" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Sedation and impaired driving.", "Heart rhythm effects.", "Movement disorders." ], "what_it_is_for": [ "Cyamemazine is encountered as an active pharmaceutical ingredient and in prescription medicines used in psychiatric care, particularly in France.", "It is also encountered in pharmaceutical analysis and research concerned with substance identity, formulation and stability." ], "standards_and_regulation": [ "The World Health Organization Collaborating Centre for Drug Statistics Methodology classifies cyamemazine under ATC code N05AA06 among phenothiazine antipsychotics with an aliphatic side chain." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q3008033: cyamemazine", "url": "https://www.wikidata.org/wiki/Q3008033", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Cyamemazine", "url": "https://en.wikipedia.org/wiki/Cyamemazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "cyamemazine-identity", "name": "Cyamemazine identity", "description": "Establish exactly which molecular entity and material form a cyamemazine record represents.", "rationale": "Names, phenothiazine class membership and medicinal-product labels are insufficient to resolve substance identity.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Anchor recognition to molecular structure and traceable identifiers.", "findings": [ { "id": "structure-identifier-agreement", "name": "Structure and identifier agreement", "description": "Require identifiers and analytical identity evidence to refer to the same cyamemazine structure.", "questions": [ { "text": "Which verified structure, CAS number, PubChem CID and available EC identifier identify cyamemazine base, and do all records agree?", "kind": "definition", "id": "structure-identifier-agreement-q01" }, { "text": "What reference material and analytical evidence distinguish this sample from related phenothiazines?", "kind": "measurement", "id": "structure-identifier-agreement-q02" } ] } ] }, { "id": "base-salt-boundary", "name": "Base and salt boundary", "description": "Represent material forms without treating every cyamemazine-containing material as the free base.", "findings": [ { "id": "form-and-stereochemistry", "name": "Form and stereochemical specification", "description": "Keep counterion, stoichiometry, solvation and stereochemical information explicit where established.", "questions": [ { "text": "Does the record describe cyamemazine base, tartrate or another demonstrated form, and what evidence establishes its composition?", "kind": "boundary", "id": "form-and-stereochemistry-q01" }, { "text": "What stereochemical composition is specified for cyamemazine and any counterion, and what remains unspecified?", "kind": "definition", "id": "form-and-stereochemistry-q02" } ] } ] } ] }, { "id": "content-and-quality", "name": "Content and quality", "description": "Determine how much cyamemazine is present and whether the surrounding composition supports an intended use.", "rationale": "A cyamemazine assay can be misleading when its mass basis, impurities or grade are missing.", "layers": [ { "id": "quantity-basis", "name": "Quantity basis", "description": "Make cyamemazine content interpretable across base, salt and solution records.", "findings": [ { "id": "base-equivalent-accounting", "name": "Base-equivalent accounting", "description": "Permit conversions only from verified composition and clearly stated assay conventions.", "questions": [ { "text": "Is the reported amount cyamemazine base equivalent, total salt mass or concentration of a specified preparation?", "kind": "measurement", "id": "base-equivalent-accounting-q01" }, { "text": "Which verified stoichiometry, molecular masses, water content and assay basis justify a conversion?", "kind": "action", "id": "base-equivalent-accounting-q02" } ] } ] }, { "id": "analytical-suitability", "name": "Analytical suitability", "description": "Assess cyamemazine identity, related substances and grade using batch-specific evidence.", "findings": [ { "id": "parent-and-impurity-resolution", "name": "Parent and impurity resolution", "description": "Require suitable separation and quantification before interpreting purity or accepting a batch.", "questions": [ { "text": "Which method resolves cyamemazine from relevant synthesis impurities and degradation products, with what detection and quantification limits?", "kind": "measurement", "id": "parent-and-impurity-resolution-q01" }, { "text": "Which certificate, specification and reference-standard traceability support the claimed analytical or pharmaceutical grade?", "kind": "provenance", "id": "parent-and-impurity-resolution-q02" } ] } ] } ] }, { "id": "physical-behaviour-and-stability", "name": "Physical behaviour and stability", "description": "Relate cyamemazine material properties to its form, environment and exposure history.", "rationale": "Properties measured for one salt, solid form or solution cannot automatically govern another.", "layers": [ { "id": "form-dependent-properties", "name": "Form-dependent properties", "description": "Record physical constants with the conditions and material identity needed to use them.", "findings": [ { "id": "conditional-property-evidence", "name": "Conditional property evidence", "description": "Separate measured cyamemazine properties from estimates and values belonging to salts or formulations.", "questions": [ { "text": "What phase, thermal transitions and decomposition behaviour are measured for the specified cyamemazine form?", "kind": "measurement", "id": "conditional-property-evidence-q01" }, { "text": "What solubility, pKa and partition measurements are available, with solvent, pH, temperature and experimental or predicted status?", "kind": "measurement", "id": "conditional-property-evidence-q02" } ] } ] }, { "id": "exposure-and-retest", "name": "Exposure and retest", "description": "Connect storage decisions to demonstrated stability of the actual material.", "findings": [ { "id": "stability-supported-condition", "name": "Stability-supported condition", "description": "Assess whether temperature, light, oxygen, moisture or solution preparation have changed suitability.", "questions": [ { "text": "Which stability studies establish relevant degradation pathways and storage conditions for this cyamemazine form?", "kind": "provenance", "id": "stability-supported-condition-q01" }, { "text": "After a recorded exposure or storage excursion, which evidence supports continued use, retesting or rejection?", "kind": "action", "id": "stability-supported-condition-q02" } ] } ] } ] }, { "id": "biological-activity-boundaries", "name": "Biological activity boundaries", "description": "Connect cyamemazine to pharmacological evidence without making substance identity a treatment recommendation.", "rationale": "Molecular activity, metabolite activity and medicinal-product outcomes answer different questions.", "layers": [ { "id": "target-evidence", "name": "Target evidence", "description": "Represent receptor interactions through comparable, source-specific experimental results.", "findings": [ { "id": "assay-qualified-activity", "name": "Assay-qualified activity", "description": "Require target identity, assay context and endpoint before comparing cyamemazine activity.", "questions": [ { "text": "Which dopamine, serotonin or other receptor interactions are supported by directly inspected cyamemazine studies?", "kind": "provenance", "id": "assay-qualified-activity-q01" }, { "text": "For each result, what species, assay, endpoint, concentration units and uncertainty distinguish binding affinity from functional activity?", "kind": "measurement", "id": "assay-qualified-activity-q02" } ] } ] }, { "id": "parent-metabolite-product-links", "name": "Parent, metabolite and product links", "description": "Keep biological transformations and clinical observations attached to their actual subjects.", "findings": [ { "id": "attribution-of-biological-effects", "name": "Attribution of biological effects", "description": "Prevent metabolite findings or product-specific observations from being silently assigned to isolated parent cyamemazine.", "questions": [ { "text": "Which metabolites are identified by reliable evidence, and which reported activities belong to them rather than parent cyamemazine?", "kind": "boundary", "id": "attribution-of-biological-effects-q01" }, { "text": "Which findings concern isolated cyamemazine, and which depend on a medicinal product, administration route or patient population?", "kind": "boundary", "id": "attribution-of-biological-effects-q02" } ] } ] } ] }, { "id": "handling-and-regulatory-constraints", "name": "Handling and regulatory constraints", "description": "Determine applicable controls for the identified cyamemazine material and intended activity.", "rationale": "Bulk-substance handling and medicinal-product permissions require different evidence and cannot be inferred from a shared active ingredient.", "layers": [ { "id": "material-exposure-controls", "name": "Material exposure controls", "description": "Assess occupational and environmental handling using form-specific hazard evidence.", "findings": [ { "id": "supported-hazard-controls", "name": "Supported hazard controls", "description": "Tie handling decisions to an applicable safety data sheet and documented exposure assessment.", "questions": [ { "text": "Which current SDS and GHS classification apply to this cyamemazine form, purity and jurisdiction?", "kind": "provenance", "id": "supported-hazard-controls-q01" }, { "text": "What established exposure limits or documented control basis govern weighing, spill response and disposal when cyamemazine-specific limits are unavailable?", "kind": "action", "id": "supported-hazard-controls-q02" } ] } ] }, { "id": "jurisdiction-and-permitted-use", "name": "Jurisdiction and permitted use", "description": "Connect legal and quality constraints to a specified location, date and activity.", "findings": [ { "id": "activity-specific-permissions", "name": "Activity-specific permissions", "description": "Evaluate acquisition, supply and use through applicable substance and product records.", "questions": [ { "text": "Which dated jurisdictional records govern acquiring, importing, supplying or using cyamemazine for the proposed activity?", "kind": "action", "id": "activity-specific-permissions-q01" }, { "text": "Which permissions and restrictions attach to bulk cyamemazine, and which attach only to a particular authorised medicinal product?", "kind": "boundary", "id": "activity-specific-permissions-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify substance identifiers and distinguish free-base identity from salt identity before registering CAS, EC or PubChem records.", "Check current national product information for indications and safety details; melting point, solubility, GHS classification and exposure limits are not confidently recalled." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Cyamemazine free base", "Cyamemazine tartrate salt" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "cyamemazine", "note": "Names the active substance rather than a particular medicinal product." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "N05AA06", "note": "Classified among phenothiazine antipsychotics with an aliphatic side chain." }, { "scheme": "Molecular formula", "value_or_pattern": "C19H21N3S", "note": "For the neutral free base; the tartrate salt has a different composition." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active ingredient in prescription antipsychotic medicines.", "Treatment of psychotic disorders.", "Sedative and anxiolytic treatment in selected clinical settings, subject to locally authorised indications." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the free base", "typical_range": "323.46", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Sedation and impaired alertness, potentially intensified by alcohol or other central nervous system depressants.", "Orthostatic hypotension.", "Anticholinergic effects, including constipation, dry mouth and urinary retention.", "QT prolongation and potentially serious cardiac arrhythmias.", "Movement disorders and rare neuroleptic malignant syndrome associated with antipsychotic treatment." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Particularly associated with prescribing in France, where Tercian is a trade name.", "Availability, approved indications and product formulations depend on national medicinal-product authorisations." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Chlorpromazine", "difference": "A related phenothiazine antipsychotic with a chlorine ring substituent; cyamemazine has a cyano substituent and a different side-chain structure." }, { "name": "Cyamemazine tartrate", "difference": "A salt form containing tartrate, distinguished from the neutral free base by composition and formula mass." }, { "name": "Tercian", "difference": "A medicinal-product trade name; cyamemazine is the active chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of cyamemazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "What authoritative identifier set, stereochemical specification and salt stoichiometry should govern cyamemazine base and each linked material form?", "Which experimentally supported physical constants and stability conditions exist for the free base versus tartrate, including whether reported thermal values describe melting or decomposition?", "Which validated analytical methods, impurity limits and grade specifications are available for assessing cyamemazine batches?", "Which directly inspected studies establish parent and metabolite pharmacology, and how comparable are their assays?", "What current form-specific GHS classifications, occupational exposure limits and jurisdictional restrictions apply, and where is evidence absent?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }